, Volume 9, Issue 1, pp 4-5,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 16 Dec 2010

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy

This is an excerpt from the content

Trial

Grey A, Boland M, Wattie D, et al.: Prolonged antiresorptive activity of zoledronate: a randomized control trial. Gen Bone Miner Res 2010, 25:2251–2255.

Introduction

Zoledronic acid (ZA) is a potent nitrogen-containing bisphosphonate with a long skeletal half-life that is administered annually by intravenous (IV) infusion. In the Horizon trial, ZA significantly reduced the risk of vertebral fracture by 70%, the risk of hip fracture by 40%, and the risk of nonvertebral fracture by 20% [1]. ZA also reduced the risk of clinical fracture by 35% and decreased mortality by 28% after hip fracture in the Recurrent Fracture Trial [2]. A combination of antifracture efficacy, low rate of adverse events, and infrequent dosing make it a desirable agent for the future.

Aims

Defining the duration of action of zoledronate and the optimal dosing interval may help reduce the cost of an effective therapy.

Methods

Andrew Grey performed a 3-year randomized placebo-controlled trial of the effects on bone tur